The import of finished medicines to Russia exceeded 244 billion rubles in H1 2018
22 August 2018
According to the results of the first half of 2018, imports of finished mediñinal drugs to Russia amounted to 244.3 billion rubles (in prices of release for free circulation). Deliveries of in-bulk products during the same period reached 52 billion rubles. Year over year growth comparing to the same period in 2017 when calculating in rubles amounted to 2% for finished forms, the supply of bulk products increased by 22% for the year.
Russia may start using own quadrivalent influenza vaccine from 2019
21 August 2018
This was announced by Anna Popova, Head of Rospotrebnadzor, Chief Sanitary Doctor of the Russian Federation. “As our scientists-developers have assured us, the quadrivalent vaccine will be available by the end of this year. Therefore in the next year’s season we will be able to vaccinate against all four strains,” Mrs. Popova said.
Russian researchers developed a complex gene therapy drug
21 August 2018
Russian researchers have developed a complex antitumor gene therapy drug. They have already carried out preclinical testing of cancer drug called AntionkoRAN-M. Two genes (a cell killer and an immunostimulatory molecule) are enclosed in a polymer shell which plays role of a drug delivery vehicle. Experts believe that such innovative drug will stand for the future of oncology, since it does not have as many side effects as chemotherapy or radiotherapy.
Russian scientists are exploring the use of bacteria for targeted drug delivery
20 August 2018
Russian physicists will be able to control the movement of bacteria for the treatment of cardiovascular diseases. For this purpose in collaboration with microbiologists, they established a laboratory at the Moscow Institute of Physics and Technology, according to information from the Joint Institute for High Temperatures (JIHT) of the Russian Academy of Sciences.
The top five Russian biotech startups are Skolkovo residents
17 August 2018
Rusbase, an independent website devoted to technology, business and investment, published a list of the top five most interesting biotech startups in Russia, and all are residents of the Skolkovo Foundation.
Russia has prepared a medical industry development strategy up to 2030
17 August 2018
The Ministry of Industry and Trade of the Russian Federation prepared a draft decree of the Government of the Russian Federation “On the approval of the Strategy for the Development of the Medical Industry of the Russian Federation for the Period up to 2030”.
Researchers developed a new class of drugs to reduce cardiovascular risk
16 August 2018
Researchers from Cleveland Clinic (Cleveland, Ohio, USA) have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.
What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?
15 August 2018
As a small biotech company proceeds from startup phase through rapid growth of its operations, it will face many critical decisions along the way. Indeed, many of the decisions will be pivotal to determining whether the company will successfully move from a small incubator of ideas to the ability to shepherd a R&D asset through its pipeline to achieving commercial success. This article will provide readers with selected examples of such decisions, plus questions or factors to be considered when making decisions that will have significant impact on the future of their growing firm.
15 August 2018
M&A-driven dealmaking in 2018 across the biopharmaceutical industry is on track to becoming the second highest of the decade. “There’s been a significant increase in private financing, principally driven by Series A financing, which tells us that new company formation has accelerated in the last four to five years,” says Neel Patel, managing director, commercial strategy and planning, at Syneos Health Consulting, and co-author of theNeel Patel 2018 Dealmakers’ Intention Study.
FPI conducts preclinical trials of drug intended to save seriously injured
14 August 2018
Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024